Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
06:00am, Friday, 29'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage
Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions
12:06pm, Thursday, 28'th May 2026
NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
06:00am, Thursday, 28'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first patients in SIgnatera-Guided iNterventionA
Baron Health Care Fund Q1 2026 Portfolio Activity
03:16pm, Wednesday, 27'th May 2026
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides test
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
07:34am, Wednesday, 27'th May 2026
Natera gets buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue guidance. NTRA's Q1 revenue grew 38% YoY, with test volumes up 18.5%, reflecting str
Natera Expands Austin Operations With New Sequencing Facility
12:01pm, Tuesday, 26'th May 2026
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
06:00am, Tuesday, 26'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive p
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
05:05pm, Thursday, 21'st May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
01:31pm, Thursday, 21'st May 2026
NTRA's EXPAND trial for Fetal Focus single-gene NIPT tops 2,000 patients, doubling in a year as new data spotlight its robust design.
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
07:00am, Thursday, 21'st May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milesto
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
03:35pm, Wednesday, 20'th May 2026
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
07:00am, Wednesday, 20'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
11:50am, Monday, 18'th May 2026
Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
12:45pm, Friday, 15'th May 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Sign
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
02:30pm, Sunday, 10'th May 2026
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (
